Request for the Technical Review of 22 Draft Skin Notation Assignments and Skin Notation Profiles, 22148-22150 [2010-9693]
Download as PDF
<![CDATA[
mstockstill on DSKH9S0YB1PROD with NOTICES
22148
Federal Register / Vol. 75, No. 80 / Tuesday, April 27, 2010 / Notices
Line for up-to-date information on this
meeting. A notice in the Federal
Register about last minute modifications
that impact a previously announced
advisory committee meeting cannot
always be published quickly enough to
provide timely notice. Therefore, you
should always check the agency’s Web
site and call the appropriate advisory
committee hot line/phone line to learn
about possible modifications before
coming to the meeting.
Agenda: On June 8 and 9, 2010, the
subcommittee will receive presentations
and discuss the development of a list of
harmful or potentially harmful
constituents, including smoke
constituents, in tobacco products.
Topics for discussion will include the
criteria for selection of the constituents,
developing a proposed list of harmful or
potentially harmful constituents, the
rationale for including each constituent,
and the acceptable analytical methods
for assessing the quantity of each
constituent. A second meeting of this
subcommittee, to continue these
discussions as necessary and to include
ancillary and normalization standards
for the constituents, will be scheduled
for the summer of 2010.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before May 28, 2010. Oral
presentations from the public will be
scheduled between approximately 2:45
p.m. and 3:45 p.m. on June 8, 2010.
Those desiring to make formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before May 20,
2010. Time allotted for each
presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
VerDate Nov<24>2008
16:09 Apr 26, 2010
Jkt 220001
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by May 21, 2010.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Karen
Templeton-Somers at least 7 days in
advance of the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/
AdvisoryCommittees/AboutAdvisory
Committees/ucm111462.htm for
procedures on public conduct during
advisory committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: April 21, 2010.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
[FR Doc. 2010–9662 Filed 4–26–10; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket Number NIOSH–153–A]
Request for the Technical Review of 22
Draft Skin Notation Assignments and
Skin Notation Profiles
AGENCY: National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC),
Department of Health and Human
Services (HHS).
ACTION: Notice of public comment
period.
SUMMARY: The National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC) is
conducting a public review of the draft
skin notations and support technical
documents entitled ‘‘Skin Notations
Profiles, for 22 chemicals.’’ NIOSH is
requesting technical reviews of the draft
Skin Notation Profiles. To facilitate the
review of these documents, NIOSH
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
requests that the following questions be
taken into consideration:
1. Does this document clearly outline
the systemic health hazards associated
with exposures of the skin to the
chemical? If not, what specific
information is missing from the
document?
2. If the SYS or SYS (FATAL)
notations are assigned, is the rationale
and logic behind the assignment clear?
If not assigned, is the logic clear why it
was not (e.g., insufficient data, no
identified health hazard)?
3. Does this document clearly outline
the direct (localized) health hazards
associated with exposures of the skin to
the chemical? If not, what specific
information is missing from the
document?
4. If the DIR, DIR (IRR), or DIR (COR)
notations are assigned, is the rationale
and logic behind the assignment clear?
If not assigned, is the logic clear why it
was not (e.g., insufficient data, no
identified health hazard)?
5. Does this document clearly outline
the immune-mediated responses
(allergic response) health hazards
associated with exposures of the skin to
the chemical? If not, what specific
information is missing from the
document?
6. If the SEN notation is assigned, is
the rationale and logic behind the
assignment clear? If not assigned, is the
logic clear why it was not (e.g.,
insufficient data, no identified health
hazard)?
7. If the ID(SK) or SK were assigned,
is the rationale and logic outlined
within the document?
8. Are the conclusions supported by
the data?
9. Are the tables clear and
appropriate?
10. Is the document organized
appropriately? If not, what
improvements are needed?
11. Is the language of the manuscript
acceptable as written? If not, what
improvements are needed?
12. Are you aware of any scientific
data reported in governmental
publications, databases, peer-reviewed
journals, or other sources that should be
included within this document?
13. What is your final
recommendation for this manuscript?
Public Comment Period: Comments
must be received by June 11, 2010.
ADDRESSES: You may submit comments,
identified by docket number NIOSH–
153–A, by any of the following methods:
• Mail: NIOSH Docket Office, Robert
A. Taft Laboratories, MS–C34, 4676
Columbia Parkway, Cincinnati, OH
45226.
E:\FR\FM\27APN1.SGM
27APN1
Federal Register / Vol. 75, No. 80 / Tuesday, April 27, 2010 / Notices
• Facsimile: (513) 533–8285.
• E-mail: nioshdocket@cdc.gov. All
information received in response to this
notice will be available for public
examination and copying at the NIOSH
Docket Office, 4676 Columbia Parkway,
Cincinnati, Ohio 45226. A complete
electronic docket containing all
comments submitted will be available
on the NIOSH Web page at https://
www.cdc.gov/niosh/docket, and
comments will be available in writing
by request. NIOSH includes all
comments received without change in
the docket, including any personal
information provided.
FOR FURTHER INFORMATION CONTACT: G.
Scott Dotson, NIOSH, Robert A Taft
Laboratories, MS–C32, 4676 Columbia
Parkway, Cincinnati, OH 45226,
telephone (513)533–8540.
SUPPLEMENTARY INFORMATION: In 2009,
NIOSH published Current Intelligence
Bulletin (CIB) 61: A Strategy for
Assigning New NIOSH Skin Notations
[NIOSH 2009–147; available at https://
www.cdc.gov/niosh/docs/2009–147/
pdfs/2009–147.pdf]. The CIB presents a
strategic framework that is a form of
hazard identification that has been
designed to do the following:
1. Ensure that the assigned skin
notations reflect the contemporary state
of scientific knowledge.
2. Provide transparency behind the
assignment process.
3. Communicate the hazards of
chemical exposures of the skin.
4. Meet the needs of health
professionals, employers, and other
interested parties in protecting workers
from chemical contact with the skin.
This strategy involves the assignment
of multiple skin notations for
distinguishing systemic (SYS), direct
(DIR), and sensitizing (SEN) effects
caused by exposure of skin (SK) to
chemicals. Chemicals that are highly or
extremely toxic and may be potentially
lethal or life-threatening following
exposures of the skin are designated
with the systemic subnotation (FATAL).
Potential irritants and corrosive
chemicals are indicated by the direct
effects subnotations (IRR) and (COR),
respectively. Thus with the new
strategy, chemicals labeled as SK: SYS
are recognized to contribute to systemic
toxicity through dermal absorption.
Chemicals assigned the notation SK:
SYS (FATAL) have been identified as
highly or extremely toxic and have the
potential to be lethal or life-threatening
following acute contact with the skin.
Substances identified to cause direct
effects (i.e., damage or destruction) to
the skin limited to or near the point of
contact are labeled SK: DIR, and those
resulting in skin irritation and corrosion
at the point of contact are labeled as SK:
DIR (IRR) and SK: DIR (COR),
respectively. The SK: SEN notation is
used for substances identified as
causing or contributing to allergic
contact dermatitis (ACD) or other
immune-mediated responses, such as
airway hyper reactivity (asthma).
Candidate chemicals may be assigned
more than one skin notation when they
are identified to cause multiple effects
resulting from skin exposure. For
example, if a chemical is identified as
corrosive and also contributes to
systemic toxicity, it will be labeled as
Document #
mstockstill on DSKH9S0YB1PROD with NOTICES
A–01
A–02
A–03
A–04
..............................
..............................
..............................
..............................
A–05
A–06
A–07
A–08
A–09
A–10
A–11
A–12
A–13
A–14
A–15
A–16
A–17
A–18
A–19
A–20
A–21
A–22
..............................
..............................
..............................
..............................
..............................
..............................
..............................
..............................
..............................
..............................
..............................
..............................
..............................
..............................
..............................
..............................
..............................
..............................
VerDate Nov<24>2008
22149
SK: SYS–DIR (COR). When scientific
data for a chemical indicate that skin
exposure does not produce systemic,
direct, or sensitizing effects, the
compound will be assigned the notation
(SK). The ID(SK) notation is assigned to
indicate that insufficient data on the
health hazards associated with skin
exposure to a substance exist at the time
of the review to determine whether the
chemical has the potential to act as a
systemic, direct, or sensitizing agent.
The ND notation indicates that a
chemical has not been evaluated by the
strategy outlined in this CIB and that the
health hazards associated with skin
exposure are unknown.
Historically, skin notations have been
published in the NIOSH Pocket Guide to
Chemical Hazards [NIOSH 2005–149].
This practice will continue with the
NIOSH skin notation assignments for
each evaluated chemical being
integrated as they become available. A
support document called a Skin
Notation Profile has been developed for
each evaluated chemical. The Skin
Notation Profile for a chemical is
intended to provide information
supplemental to the skin notation,
including a summary of all relevant data
used to aid in determining the hazards
associated with skin exposures.
NIOSH seeks comments on the draft
skin notation assignments and Skin
Notation Profiles for 22 chemicals. The
draft Skin Notation Profiles were
developed to provide the scientific
rationale behind the hazard-specific
skin notation (SK) assignments for the
following chemicals:
Substance(s)
1,3-Dichloropropene (CAS# 542–75–6).
Phenol (CAS# 108–95–2).
Hydrogen fluoride/hydrofluoric acid (CAS# 7664–39–3).
Dinitrotoluene, (CAS# 25321–14–6); 2,4–.
Dinitrotoluene (CAS# 121–14–2); 2,6–.
Dinitrotoluene (CAS# 606–20–2).
Acrylamide (CAS# 79–06–1).
Acrylonitrile (CAS# 107–13–1).
Metallic Chromium and other Substances containing Hexavalent Chromium [Cr(VI)] CAS# 7440–47–3; 18540–29–9).
m,p,o-Dinitrobenzene (CAS# 99–65–0; CAS# 528–29–0; CAS# 100–25–4).
Epichlorohydrin (CAS# 106–89–8).
Ethylene glycol dinitrate (CAS# 628–96–6).
Bisphenol A (CAS# 80–05–7).
Formaldehyde (CAS# 50–00–0).
Hydrazine (CAS# 302–01–2).
Nitroglycerin (CAS# 55–63–0).
Nonane (CAS# 111–84–2).
Glutaraldehyde (CAS# 111–30–8).
Sodium hydroxide (CAS# 1310–73–2).
Trichloroethylene (CAS# 79–01–6).
Methyl cellosolve (CAS# 109–86–4).
2-Butoxyethanol (CAS# 111–76–2).
2-Ethoxyethanol (CAS# 110–80–5).
p-Phenylenediamine (CAS # 106–50–3).
16:09 Apr 26, 2010
Jkt 220001
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
E:\FR\FM\27APN1.SGM
27APN1
22150
Federal Register / Vol. 75, No. 80 / Tuesday, April 27, 2010 / Notices
Each Skin Notation Profile provides a
detailed summary of the health hazards
of skin contact and rationale for the
proposed SK assignment with the
chemical(s)-of-interest.
Dated: April 19, 2010.
John Howard,
Director, National Institute for Occupational
Safety and Health, Centers for Disease Control
and Prevention.
[FR Doc. 2010–9693 Filed 4–26–10; 8:45 am]
BILLING CODE 4163–19–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of Laboratories Which
Meet Minimum Standards To Engage in
Urine Drug Testing for Federal
Agencies
Correction
In notice document 2010–7170
beginning on page 16813 in the issue of
Friday, April 2, 2010, make the
following correction:
On page 16814, in the first column, in
the list following the second full
paragraph, the listings for ACM Medical
Laboratory, Inc. and Advanced
Toxicology Network were combined.
The listings should be separated and
read as follows:
ACM Medical Laboratory, Inc.,160
Elmgrove Park,Rochester, NY
14624,585-429-2264;
Advanced Toxicology Network,3560
Air Center Cove, Suite 101,Memphis,
TN 38118,901-794-5770 / 888-290-1150;
[FR Doc. C1–2010–7170 Filed 4–26–10; 8:45 am]
BILLING CODE 1505–01–D
DEPARTMENT OF HOMELAND
SECURITY
Coast Guard
[Docket No. USCG–2010–0281]
Certificate of Alternative Compliance
for the Ferry Boat CHARLEVOIX
Coast Guard, DHS.
Notice.
AGENCY:
mstockstill on DSKH9S0YB1PROD with NOTICES
ACTION:
SUMMARY: The Coast Guard announces
that a Certificate of Alternative
Compliance was issued for the ferry
boat CHARLEVOIX as required by 33
U.S.C. 1605(c) and 33 CFR 81.18.
DATES: The Certificate of Alternative
Compliance was issued on April 2,
2010.
ADDRESSES: The docket for this notice is
available for inspection or copying at
VerDate Nov<24>2008
18:34 Apr 26, 2010
Jkt 220001
the Docket Management Facility (M–30),
U.S. Department of Transportation,
West Building Ground Floor, Room
W12–140, 1200 New Jersey Avenue, SE.,
Washington, DC 20590, between 9 a.m.
and 5 p.m., Monday through Friday,
except Federal holidays. You may also
find this docket on the Internet by going
to https://www.regulations.gov, inserting
USCG–2010–0281 in the ‘‘Keyword’’
box, and then clicking ‘‘Search.’’
FOR FURTHER INFORMATION CONTACT: If
you have questions on this notice, call
LCDR Wm. Erik Pickering, District Nine,
Prevention Branch, U.S. Coast Guard,
telephone 216–902–6050. If you have
questions on viewing or submitting
material to the docket, call Renee V.
Wright, Program Manager, Docket
Operations, telephone 202–366–9826.
SUPPLEMENTARY INFORMATION:
Background and Purpose
A Certificate of Alternative
Compliance, as allowed under Title 33
of the Code of Federal Regulations, Parts
81 and 89, has been issued for the ferry
boat CHARLEVOIX. Full compliance
with 72 COLREGS and the Inland Rules
Act would hinder the vessel’s ability to
operate as designed. Because of the
design of the ferry boat CHARLEVOIX,
operation of its whistle at the level
required in Rule 34 (g) of 72 COLREGS
and the Inland Rules Act (33 USC 2001
et. seq.) would subject passengers and
crew to dangerous and unacceptable
decibel levels. The National Institute for
Occupational Safety and Health states
that exposure to sounds over 85 decibels
for periods greater than eight hours will
cause permanent hearing damage. The
crew on the ferry boat CHARLEVOIX
works eight hour shifts. Thus, if the
ferry boat CHARLEVOIX were to
comply with Rule 34 (g) its crew would
potentially suffer permanent hearing
loss.
The Commandant, U.S. Coast Guard,
certifies that full compliance with the
Inland Rules Act would interfere with
the normal functions/intent of the vessel
and would not significantly enhance the
safety of the vessel’s operation.
Requiring the vessel to sound a
prolonged whistle/horn blast at the
required decibel level prior to each
departure (approximately every 5.3
minutes, in a 16 hour period/7 days per
week operation) would subject the crew
and passengers to unacceptable decibel
levels, and not improve overall vessel
safety.
The Certificate of Alternative
Compliance allows for the reducing of
the intensity of the required sound
signal to 85 decibel when leaving the
dock/berth during normal operations
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
provided the following conditions are
met: A secondary whistle must be
installed that meets the requirements of
Rule 34 (g) and be used when operating
in restricted visibility as per Rule 35 or
to reduce the risk of collision as per
Rule 34 (d).
This notice is issued under authority
of 33 U.S.C. 1605(c), and 33 CFR 81.18.
Dated: April 2, 2010.
L.W. Thomas,
Captain, U.S. Coast Guard, Chief, Inspections
and Investigations Branch, By Direction of
the Commander, Ninth Coast Guard District.
[FR Doc. 2010–9682 Filed 4–26–10; 8:45 am]
BILLING CODE 9110–04–P
DEPARTMENT OF HOMELAND
SECURITY
Federal Emergency Management
Agency
[Internal Agency Docket No. FEMA–3311–
EM; Docket ID FEMA–2010–0002]
Rhode Island; Amendment No. 2 to
Notice of an Emergency Declaration
AGENCY: Federal Emergency
Management Agency, DHS.
ACTION:
Notice.
SUMMARY: This notice amends the notice
of an emergency declaration for the
State of Rhode Island (FEMA–3311–
EM), dated March 30, 2010, and related
determinations.
DATES:
Effective Date: April 12, 2010.
FOR FURTHER INFORMATION CONTACT:
Peggy Miller, Recovery Directorate,
Federal Emergency Management
Agency, 500 C Street, SW., Washington,
DC 20472, (202) 646–3886.
Notice is
hereby given that the incident period for
this emergency is closed effective April
12, 2010.
SUPPLEMENTARY INFORMATION:
(The following Catalog of Federal Domestic
Assistance Numbers (CFDA) are to be used
for reporting and drawing funds: 97.030,
Community Disaster Loans; 97.031, Cora
Brown Fund; 97.032, Crisis Counseling;
97.033, Disaster Legal Services; 97.034,
Disaster Unemployment Assistance (DUA);
97.046, Fire Management Assistance Grant;
97.048, Disaster Housing Assistance to
Individuals and Households In Presidentially
Declared Disaster Areas; 97.049,
Presidentially Declared Disaster Assistance—
Disaster Housing Operations for Individuals
and Households; 97.050, Presidentially
Declared Disaster Assistance to Individuals
and Households—Other Needs; 97.036,
Disaster Grants—Public Assistance
E:\FR\FM\27APN1.SGM
27APN1
]]>Agencies
[Federal Register Volume 75, Number 80 (Tuesday, April 27, 2010)]
[Notices]
[Pages 22148-22150]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-9693]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket Number NIOSH-153-A]
Request for the Technical Review of 22 Draft Skin Notation
Assignments and Skin Notation Profiles
AGENCY: National Institute for Occupational Safety and Health (NIOSH)
of the Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of public comment period.
-----------------------------------------------------------------------
SUMMARY: The National Institute for Occupational Safety and Health
(NIOSH) of the Centers for Disease Control and Prevention (CDC) is
conducting a public review of the draft skin notations and support
technical documents entitled ``Skin Notations Profiles, for 22
chemicals.'' NIOSH is requesting technical reviews of the draft Skin
Notation Profiles. To facilitate the review of these documents, NIOSH
requests that the following questions be taken into consideration:
1. Does this document clearly outline the systemic health hazards
associated with exposures of the skin to the chemical? If not, what
specific information is missing from the document?
2. If the SYS or SYS (FATAL) notations are assigned, is the
rationale and logic behind the assignment clear? If not assigned, is
the logic clear why it was not (e.g., insufficient data, no identified
health hazard)?
3. Does this document clearly outline the direct (localized) health
hazards associated with exposures of the skin to the chemical? If not,
what specific information is missing from the document?
4. If the DIR, DIR (IRR), or DIR (COR) notations are assigned, is
the rationale and logic behind the assignment clear? If not assigned,
is the logic clear why it was not (e.g., insufficient data, no
identified health hazard)?
5. Does this document clearly outline the immune-mediated responses
(allergic response) health hazards associated with exposures of the
skin to the chemical? If not, what specific information is missing from
the document?
6. If the SEN notation is assigned, is the rationale and logic
behind the assignment clear? If not assigned, is the logic clear why it
was not (e.g., insufficient data, no identified health hazard)?
7. If the ID\(SK)\ or SK were assigned, is the rationale and logic
outlined within the document?
8. Are the conclusions supported by the data?
9. Are the tables clear and appropriate?
10. Is the document organized appropriately? If not, what
improvements are needed?
11. Is the language of the manuscript acceptable as written? If
not, what improvements are needed?
12. Are you aware of any scientific data reported in governmental
publications, databases, peer-reviewed journals, or other sources that
should be included within this document?
13. What is your final recommendation for this manuscript?
Public Comment Period: Comments must be received by June 11, 2010.
ADDRESSES: You may submit comments, identified by docket number NIOSH-
153-A, by any of the following methods:
Mail: NIOSH Docket Office, Robert A. Taft Laboratories,
MS-C34, 4676 Columbia Parkway, Cincinnati, OH 45226.
[[Page 22149]]
Facsimile: (513) 533-8285.
E-mail: nioshdocket@cdc.gov. All information received in
response to this notice will be available for public examination and
copying at the NIOSH Docket Office, 4676 Columbia Parkway, Cincinnati,
Ohio 45226. A complete electronic docket containing all comments
submitted will be available on the NIOSH Web page at https://www.cdc.gov/niosh/docket, and comments will be available in writing by
request. NIOSH includes all comments received without change in the
docket, including any personal information provided.
FOR FURTHER INFORMATION CONTACT: G. Scott Dotson, NIOSH, Robert A Taft
Laboratories, MS-C32, 4676 Columbia Parkway, Cincinnati, OH 45226,
telephone (513)533-8540.
SUPPLEMENTARY INFORMATION: In 2009, NIOSH published Current
Intelligence Bulletin (CIB) 61: A Strategy for Assigning New NIOSH Skin
Notations [NIOSH 2009-147; available at https://www.cdc.gov/niosh/docs/2009-147/pdfs/2009-147.pdf]. The CIB presents a strategic framework
that is a form of hazard identification that has been designed to do
the following:
1. Ensure that the assigned skin notations reflect the contemporary
state of scientific knowledge.
2. Provide transparency behind the assignment process.
3. Communicate the hazards of chemical exposures of the skin.
4. Meet the needs of health professionals, employers, and other
interested parties in protecting workers from chemical contact with the
skin.
This strategy involves the assignment of multiple skin notations
for distinguishing systemic (SYS), direct (DIR), and sensitizing (SEN)
effects caused by exposure of skin (SK) to chemicals. Chemicals that
are highly or extremely toxic and may be potentially lethal or life-
threatening following exposures of the skin are designated with the
systemic subnotation (FATAL). Potential irritants and corrosive
chemicals are indicated by the direct effects subnotations (IRR) and
(COR), respectively. Thus with the new strategy, chemicals labeled as
SK: SYS are recognized to contribute to systemic toxicity through
dermal absorption. Chemicals assigned the notation SK: SYS (FATAL) have
been identified as highly or extremely toxic and have the potential to
be lethal or life-threatening following acute contact with the skin.
Substances identified to cause direct effects (i.e., damage or
destruction) to the skin limited to or near the point of contact are
labeled SK: DIR, and those resulting in skin irritation and corrosion
at the point of contact are labeled as SK: DIR (IRR) and SK: DIR (COR),
respectively. The SK: SEN notation is used for substances identified as
causing or contributing to allergic contact dermatitis (ACD) or other
immune-mediated responses, such as airway hyper reactivity (asthma).
Candidate chemicals may be assigned more than one skin notation when
they are identified to cause multiple effects resulting from skin
exposure. For example, if a chemical is identified as corrosive and
also contributes to systemic toxicity, it will be labeled as SK: SYS-
DIR (COR). When scientific data for a chemical indicate that skin
exposure does not produce systemic, direct, or sensitizing effects, the
compound will be assigned the notation (SK). The ID(SK)
notation is assigned to indicate that insufficient data on the health
hazards associated with skin exposure to a substance exist at the time
of the review to determine whether the chemical has the potential to
act as a systemic, direct, or sensitizing agent. The ND notation
indicates that a chemical has not been evaluated by the strategy
outlined in this CIB and that the health hazards associated with skin
exposure are unknown.
Historically, skin notations have been published in the NIOSH
Pocket Guide to Chemical Hazards [NIOSH 2005-149]. This practice will
continue with the NIOSH skin notation assignments for each evaluated
chemical being integrated as they become available. A support document
called a Skin Notation Profile has been developed for each evaluated
chemical. The Skin Notation Profile for a chemical is intended to
provide information supplemental to the skin notation, including a
summary of all relevant data used to aid in determining the hazards
associated with skin exposures.
NIOSH seeks comments on the draft skin notation assignments and
Skin Notation Profiles for 22 chemicals. The draft Skin Notation
Profiles were developed to provide the scientific rationale behind the
hazard-specific skin notation (SK) assignments for the following
chemicals:
------------------------------------------------------------------------
Document Substance(s)
------------------------------------------------------------------------
A-01......................... 1,3-Dichloropropene (CAS 542-75-
6).
A-02......................... Phenol (CAS 108-95-2).
A-03......................... Hydrogen fluoride/hydrofluoric acid
(CAS 7664-39-3).
A-04......................... Dinitrotoluene, (CAS 25321-14-
6); 2,4-.
Dinitrotoluene (CAS 121-14-2);
2,6-.
Dinitrotoluene (CAS 606-20-2).
A-05......................... Acrylamide (CAS 79-06-1).
A-06......................... Acrylonitrile (CAS 107-13-1).
A-07......................... Metallic Chromium and other Substances
containing Hexavalent Chromium [Cr(VI)]
CAS 7440-47-3; 18540-29-9).
A-08......................... m,p,o-Dinitrobenzene (CAS 99-65-
0; CAS 528-29-0; CAS
100-25-4).
A-09......................... Epichlorohydrin (CAS 106-89-8).
A-10......................... Ethylene glycol dinitrate (CAS
628-96-6).
A-11......................... Bisphenol A (CAS 80-05-7).
A-12......................... Formaldehyde (CAS 50-00-0).
A-13......................... Hydrazine (CAS 302-01-2).
A-14......................... Nitroglycerin (CAS 55-63-0).
A-15......................... Nonane (CAS 111-84-2).
A-16......................... Glutaraldehyde (CAS 111-30-8).
A-17......................... Sodium hydroxide (CAS 1310-73-
2).
A-18......................... Trichloroethylene (CAS 79-01-6).
A-19......................... Methyl cellosolve (CAS 109-86-
4).
A-20......................... 2-Butoxyethanol (CAS 111-76-2).
A-21......................... 2-Ethoxyethanol (CAS 110-80-5).
A-22......................... p-Phenylenediamine (CAS 106-50-
3).
------------------------------------------------------------------------
[[Page 22150]]
Each Skin Notation Profile provides a detailed summary of the
health hazards of skin contact and rationale for the proposed SK
assignment with the chemical(s)-of-interest.
Dated: April 19, 2010.
John Howard,
Director, National Institute for Occupational Safety and Health,
Centers for Disease Control and Prevention.
[FR Doc. 2010-9693 Filed 4-26-10; 8:45 am]
BILLING CODE 4163-19-P
